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duplex examination, such as body habitus. The purpose of this study was to
determine if there was a body mass index (BMI) cutoff at which duplex
ultrasonography was not an appropriate first test to rule out a DVT.
Methods: Sequential retrospective analysis was performed on all pa-
tients who underwent a lower extremity DVT examination in a single
ICAVL center.
Results: 496 patients were entered into the study for analysis. Gender,
age, BMI, and final impressions of the lower extremity venous duplex were
entered into the database for analysis. Patientswere categorized byBMI: patient
subgroups were divided in groups of BMIs of ranges of 10 points. There was a
direct correlation between increasing BMI and increasing proportion of incon-
clusive findings on examination.20: 17%, 20-25: 12%,25-30: 9%,30-40:
14%, 40-50: 26%, 50-60: 37%, 60-70: 86%, and 70: 50%. Using the
chi-squared test, these findings are significant p .0001.
Conclusions: Elevated BMI does carry with it an increased likelihood
of equivocal findings on duplex examination. These results suggest that
patients with BMI40 should consider undergoing an alternative diagnostic
imaging modality.
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Background: The Caprini risk assessment model (RAM) is a weighted
risk stratification tool used to predict 30-day or 60-day venous thromboembo-
lism (VTE) risk. Compared to the 2005 model, the 2010 model has more
sub-categories and an additional risk factor. The 2010 RAM has not been
formally validated and the changes may alter a patient’s Caprini score and/or
the model’s ability to predict VTE risk. The Venous Thromboembolism Pre-
ventionStudy (VTEPS) is amulti-center surgery study examiningperi-operative
VTE risk factors and 60-day VTE outcomes in plastic surgery patients. The
study’s objective was to compare scores derived from the 2005 and 2010
Caprini RAM and examine their ability to predict 60-day VTE risk.
Methods: The VTEPS is a multicenter study previously described in
detail. The study utilized the 2005 Caprini RAM and assessed the incidence
of symptomatic VTE. We performed a matched observational cohort study
using the existing VTEPS database. Caprini scores using the 2005 and 2010
models were calculated and compared. Group differences in 2005 and 2010
Caprini scores were examined using the Wilcoxon Signed Rank test. De-
scriptive statistics that examined VTE incidence by stratified risk score were
generated. Differences in observed VTE rate, by stratified risk score, were
examined using Pearson’s chi-square test.
Results:When compared to 2005Caprini scores, 2010 scores were lower
in 17.6% of patients, unchanged in 23.3%, and higher in 59.2% (Fig 1). The
2010 Caprini scores increased the number of patients stratified as “super-high”
risk by three-fold. Patients classified as “super-high” risk (Caprini score 8)
using the 2005 Caprini RAM were significantly more likely to have a 60-day
VTE event when compared to patients classified as “super-high” risk using the
2010 guidelines (5.85% vs. 2.52%, P.021). There were no significant differ-
ences in observed 60-day VTE rate at any other risk level (Fig 2).
Conclusions: The 2005 version of the Caprini RAM is a validated risk
prediction tool for 60-day VTE events in adult plastic surgery patients who
require postoperative admission. We recommend that the 2005 Caprini RAM
be used to risk-stratify plastic surgery patients and guide prophylaxis decisions.
The 2010 Caprini RAM contains data-driven changes that may contribute to
improved risk stratification.However, themodel requires formal validationwith
appropriate determination of new risk levels prior to widespread adoption.
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Background: Inflammation is important throughout all stages of deep
vein thrombosis (DVT), especially in the onset of acute thrombogenesis.
Fibrinolysis, which is regulated by PAI-1, is essential for thrombus resolution.
Statins have been shown to possess pleiotropic properties that affect both
inflammation and the fibrinolytic system, independent of lowering lipids effect.
In the JUPITER trial, DVT was significantly decreased in nonhyperlipidemic
patients treated with rosuvastatin. However, the mechanism behind this effect
on DVT remains unclear. Here we investigated the anti-inflammatory and
pro-fibrinolytic properties of rosuvastatin using a mouse model of DVT.
Method: Inferior vena cava (IVC) ligation was performed to create a
DVT in C57BL/6 mice. This mouse strain is noninflammatory by nature.
Groups included: rosuvastatin treated (5mg/kg) and saline controls, start-
ing 2 days before surgery. IVCs and liver were harvested and blood samples
collected at very early time points (acute DVT) 3 hr, 6 hr and 2 days after
surgery. The IVC and its thrombus were evaluated for thrombus weight and
plasma samples for PAI-activity. In addition, gene expression of PAI-1 and
inflammatory markers (IL-6, CCL2, CRP, IL-1b, TNF) were measured in
vein wall (local effect) and liver (systemic effect).
Results: (Table). Thrombus weight was significantly decreased at day 2
post DVT in rosuvastatin mice, compared to controls, Vein wall PAI-1 gene
expression was significantly decreased at 3hr. Also, circulating active PAI-1
was significantly decreased at 6hr post DVT. IL-6 and CCL2 were signifi-
cantly decreased in vein wall at 3hr. Systemic IL-6, CRP and TNF were all
significantly decreased at 6 hours.
Conclusions:Rosuvastatin decreased inflammatorymarkers andPAI-1 in
this mouse model of DVT. An anti-inflammatory effect from rosuvastatin was
observed in the vein wall at 3hr, while a systemic effect was documented at 6hr
post thrombosis. A reduction in PAI-1 was observed both locally and systemi-
cally only in the rosuvastatin treated animals. These early anti-inflammatory and
pro-fibrinolytic effects, due to the administration of rosuvastatin, significantly
decreased thrombus weight 2 days post-IVC ligation, and suggest a potential
mechanism for rosuvastatin’s effect on DVT in the JUPITER trial.
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